ABCLAbCellera Biologics Inc.
What is the market doing?
No clear lean: in an uptrend and insiders cluster-buying, but heavily shorted (+11% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +111% vs its 200-day average.
Multiple insiders bought with their own money, the strongest form of the signal (the 90 days ending Oct 8, 2026).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ABCL is trading
AbCellera Biologics Inc. is +178% over the past year while the S&P 500 is +18%: 160 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +111%
vs 200-day average · a clear uptrend
- RSI (14)
- 49
RSI (14) · neutral
- Below its 52-week high
- 15%
Below its 52-week high
Details›
- Last close2026-10-09
- $12.55
- 1 monthS&P 500 +2.7%
- +20%
- 1 yearS&P 500 +18%
- +178%
- 5 yearsS&P 500 +88%
- −29%
- vs 50-day average$11.14
- +13%
- 52-week high
- $14.82
- 52-week low
- $2.78
- Annualised volatility
- 79%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $1.6M
| Year | Return |
|---|---|
| 2026 (year to date) | +267% |
| 2025 | +17% |
| 2024 | −49% |
| 2023 | −44% |
| 2022 | −29% |
| 2021 | −64% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 4 of 6 | +0.27% |
| Feb | 6 | 0 of 6 | −12% |
| Mar | 6 | 1 of 6 | −5.9% |
| Apr | 6 | 2 of 6 | −5.6% |
| May | 6 | 4 of 6 | +5.4% |
| Jun | 6 | 3 of 6 | +11% |
| Jul | 6 | 3 of 6 | +0.46% |
| Aug | 6 | 3 of 6 | +13% |
| Sep | 6 | 4 of 6 | +7.5% |
| Oct | 6 | 3 of 6 | −1.9% |
| Nov | 5 | 3 of 5 | −0.78% |
| Dec | 5 | 1 of 5 | −3.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.